Announcing the development milestone for the first indigenous vaccine candidateCovaxin, Bharat Biotech chairman Dr Krishna Ella said, "The collaboration with ICMR and NIV was instrumental in the development of this vaccine".
"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.
She also said: "I think AstraZeneca (their partner drug company) certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials".
Tests in animals suggest the vaccine is safe and triggers an effective immune response.
The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and overseas for the respiratory disease caused by the new coronavirus.
This is the first India-made vaccine and developed from a strain of the virus that was isolated locally and weakened under laboratory conditions.
Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika. While 129 are in the pre-clinical evaluation phase.
The latest company to announce a vaccine candidate is Bharat Biotech.
Pune-based Serum Institute of India, the world's largest vaccine maker by number of doses produced and sold globally, has also partnered to mass produce a vaccine being developed by the University of Oxford and backed by the United Kingdom government.
Chinese military have been cleared to receive a Covid-19 vaccine.
With 18,522 new coronavirus cases registered over the past 24 hours, India's nationwide tally on Tuesday morning topped 566,800, according to the Health Ministry data.